View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

RUBIS: Information relating to the total number of voting rights and s...

RUBIS: Information relating to the total number of voting rights and shares as of 31/07/2025 Paris, 11 August 2025, 5:45 pm INFORMATION ON TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES PURSUANT TO ARTICLE L.233-8 II OF THE FRENCH COMMERCIAL CODE AND ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY Date Class of shares Number of shares Number of theoretical voting rights Number of exercisable voting rights (excluding shares bought back by the Company (deprived of voting rights) and shares deprived of voting rights in accordance with art. L. 233-14...

 PRESS RELEASE

RUBIS: Déclaration de capital et de droits de vote au 31/07/2025

RUBIS: Déclaration de capital et de droits de vote au 31/07/2025 Paris, le 11 août 2025, 17h45 INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS PRÉVUES PAR L’ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L’ARTICLE 223-16 DU RÈGLEMENT GÉNÉRAL DE L’AUTORITÉ DES MARCHÉS FINANCIERS Date Catégorie d’actions Nombre d’actions Nombre de droits de vote théoriques Nombre de droits de vote exerçables(hors actions autodétenues (privées du droit de vote) et actions privées du droit de vote conformément à l’article L. 233-14 du Code de commerce) 31 juillet 2025 Actions ordinai...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Oscar Haffen Lamm
  • Oscar Haffen Lamm

Medincell: Uzedy outperformed in Q2; Olanzapine LAI still on track for...

Yesterday Teva reported Q2 2025 results, highlighted by a re-acceleration in Uzedy sales to USD54m (+24% vs css), with Teva raising the product's sales guidance to USD190-200m for FY25 from USD160m. TRx data continues to support the product's growth (3x TRx YoY), with Teva reporting >80% NBRx fr

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

RUBIS: Half-year statement on Rubis’ liquidity agreement with Exane BN...

RUBIS: Half-year statement on Rubis’ liquidity agreement with Exane BNP Paribas Paris, 7 July 2025 – 5:45 pm Pursuant to the liquidity agreement that Rubis has entered into with Exane BNP Paribas, the liquidity account presented the following balances as at the settlement date of 30 June 2025: 62,375 Rubis shares€925,747 The following trades were made in the first half of 2025: 108,137 securities were purchased for a total of €2,895,108 (646 transactions) 133,191 securities were sold for a total of €3,604,518 (939 transactions) Reminder: The previous half-year statement as of 31 Decem...

 PRESS RELEASE

RUBIS: Bilan semestriel du contrat de liquidité de Rubis contracté ave...

RUBIS: Bilan semestriel du contrat de liquidité de Rubis contracté avec la société Exane BNP Paribas Paris, le 7 juillet 2025, 17h45 Au titre du contrat de liquidité confié par la société Rubis à Exane BNP Paribas, en date de dénouement du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : 62 375 titres Rubis925 747 € Au cours du 1er semestre 2025, il a été négocié un total de : À l'achat, 108 137 titres, pour un montant de 2 895 108 € (646 transactions) À la vente, 133 191 titres, pour un montant de 3 604 518 € (939 transactions) Il est rappelé que : Lors du précéd...

Adrien Frachette ... (+2)
  • Adrien Frachette
  • Christophe-Raphaël Ganet

ODDO : Profiter du momentum des SMID, repondérer les défensives

La surperformance des Small&Midcaps au S1 reste marquée par un contexte de i/ momentum sans dynamique haussière (sauf peut-être en Italie ou en Espagne), alors que les devises impacteront T2&T3, ii/ géopolitique instable, iii/ fébrilité : les 2 plus grandes puissances économiques (Chine et USA) sont en phase de pivot et/ou présentent certaines fragilités, iv/ valorisations toujours attractives (décote de 30% par rapport aux large caps, et multiples sous leurs niveaux historiques). Nous sommes ra...

Adrien Frachette ... (+2)
  • Adrien Frachette
  • Christophe-Raphaël Ganet

ODDO : Seizing SMID momentum, reweighting defensive profiles

The outperformance of small and mid caps in H1 was marked by i/ the absence of upward revision momentum (except perhaps in Italy and Spain), while forex effects are set to dent Q2 and Q3, ii/ geopolitical turmoil, iii/ a jittery market: the two biggest economic powers (China and the US) are in a period of transition and/or showing signs of weakness, iv/ attractive valuations (30% discount to large caps and multiples below historical levels). We are reasonably optimistic about small and mid caps ...

Jeremy Garnier
  • Jeremy Garnier

ODDO : ODDO BHF Nextcap Forum: Feedback from day two

Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...

Jeremy Garnier
  • Jeremy Garnier

ODDO : ODDO BHF Nextcap Forum 2025: Feedback

Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch